KNE Kane Biotech Inc.

STEM Animal Health Appoints New President and CEO

STEM Animal Health Appoints New President and CEO
EN
13/10/2020

Underlying

KNEKane Biotech Inc.

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Kane Biotech Inc.

 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Regio...

Kane Biotech Presents revyve® Data at Diabetic Foot and Southern Region Burn Conferences Average Percent Area Reduction of 97% in 4 weeks in diabetic wounds100% diabetic wound closure in ≤ 12 weeksPreclinical sustained antibiofilm activity for a minimum of 7 days WINNIPEG, Manitoba, Nov. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V: KNE) (“Kane Biotech” or “Kane”) today announced new clinical and pre-clinical data demonstrating the performance of its FDA-cleared revyve® Antimicrobial Wound Gel and revyve Wound Gel Spray in both diabetic foot ulcer healing and burn wound infectio...

November 4, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicr...

Kane Biotech Completes U.S. FDA 510(k) Submission for revyve® Antimicrobial Wound Cleanser WINNIPEG, Manitoba, Sept. 16, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or the “Company”) today announces that it has completed a U.S. Food and Drug Administration (“FDA”) 510(k) clearance submission for its revyve® Antimicrobial Wound Cleanser. revyve Antimicrobial Wound Cleanser is the Company’s third product in its revyve product line and complimentary to Kane’s revyve Antimicrobial Wound Gel and Antimicrobial Wound Gel Spray products. This new companion product will...

September 16, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Completes Enrollment in U.S. Case Series Studies of its r...

Kane Biotech Completes Enrollment in U.S. Case Series Studies of its revyve® Antimicrobial Wound Gel and Spray WINNIPEG, Manitoba, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech” or “Kane”) today announces that it has enrolled 28 participants in its revyve® Antimicrobial Wound Gel and Spray U.S. Case Series Studies, exceeding its 25-participant target. US FDA 510(k) cleared revyve Antimicrobial Wound Gel For the clinical series, Kane engaged wound care and burn specialists in the U.S. Data is anticipated to be presented at various medical m...

September 10, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced...

Kane Biotech to Present revyve® Clinical Data at Symposium on Advanced Wound Care (SAWC) Fall Conference Clinical data to be presented demonstrates wound healing in complex wounds that were over two years old WINNIPEG, Manitoba, Sept. 04, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announces that Interim Chief Executive Officer, Dr. Robert Huizinga, will be presenting at the Symposium on Advanced Wound Care (“SAWC”) Fall conference taking place from September 3-6, 2025 in Las Vegas, Nevada. US FDA 510(k) cleared revyve An...

September 4, 2025 1 EN
 PRESS RELEASE
Free
KNE Kane Biotech In...

Kane Biotech Announces Second Quarter 2025 Financial Results

Kane Biotech Announces Second Quarter 2025 Financial Results WINNIPEG, Manitoba, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Kane Biotech Inc. (TSX-V:KNE) (“Kane Biotech”, “Kane” or the “Company”) today announced its second quarter 2025 financial results. Second Quarter 2025 Financial Highlights (Comparatives exclude discontinued STEM Animal Health “STEM” Operations): Total revenue for the three months ended June 30, 2025 was $27,997 compared to $620,437 in the three months ended June 30, 2024. Almost all revenue recorded in the comparative quarter was related to the Company’s animal health busin...

August 28, 2025 1 EN

ResearchPool Subscriptions

Get the most out of your insights

Get in touch